JP2006328073A5 - - Google Patents

Download PDF

Info

Publication number
JP2006328073A5
JP2006328073A5 JP2006157094A JP2006157094A JP2006328073A5 JP 2006328073 A5 JP2006328073 A5 JP 2006328073A5 JP 2006157094 A JP2006157094 A JP 2006157094A JP 2006157094 A JP2006157094 A JP 2006157094A JP 2006328073 A5 JP2006328073 A5 JP 2006328073A5
Authority
JP
Japan
Prior art keywords
alkyl
substituted
het
halo
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006157094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006328073A (ja
JP4815566B2 (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006328073A publication Critical patent/JP2006328073A/ja
Publication of JP2006328073A5 publication Critical patent/JP2006328073A5/ja
Application granted granted Critical
Publication of JP4815566B2 publication Critical patent/JP4815566B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006157094A 1999-04-30 2006-06-06 グルココルチコイド受容体モジュレーター Expired - Fee Related JP4815566B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13213099P 1999-04-30 1999-04-30
US60/132,130 1999-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000615356A Division JP3901945B2 (ja) 1999-04-30 2000-03-27 グルココルチコイド受容体モジュレーター

Publications (3)

Publication Number Publication Date
JP2006328073A JP2006328073A (ja) 2006-12-07
JP2006328073A5 true JP2006328073A5 (enExample) 2007-05-10
JP4815566B2 JP4815566B2 (ja) 2011-11-16

Family

ID=22452621

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000615356A Expired - Fee Related JP3901945B2 (ja) 1999-04-30 2000-03-27 グルココルチコイド受容体モジュレーター
JP2006157094A Expired - Fee Related JP4815566B2 (ja) 1999-04-30 2006-06-06 グルココルチコイド受容体モジュレーター

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000615356A Expired - Fee Related JP3901945B2 (ja) 1999-04-30 2000-03-27 グルココルチコイド受容体モジュレーター

Country Status (45)

Country Link
US (3) US6380223B1 (enExample)
EP (1) EP1175383B1 (enExample)
JP (2) JP3901945B2 (enExample)
KR (1) KR100511585B1 (enExample)
CN (2) CN100400487C (enExample)
AP (1) AP1542A (enExample)
AR (1) AR032128A1 (enExample)
AU (1) AU776608B2 (enExample)
BG (3) BG110227A (enExample)
BR (1) BR0010138B1 (enExample)
CA (2) CA2372173A1 (enExample)
CO (1) CO5280071A1 (enExample)
CR (2) CR6478A (enExample)
CU (1) CU23111A3 (enExample)
CZ (1) CZ304203B6 (enExample)
DZ (1) DZ3038A1 (enExample)
EA (2) EA007483B1 (enExample)
EE (1) EE05584B1 (enExample)
EG (1) EG25606A (enExample)
GE (1) GEP20053474B (enExample)
GT (1) GT200000053A (enExample)
HK (1) HK1042889B (enExample)
HR (1) HRP20010804B1 (enExample)
HU (1) HUP0201243A3 (enExample)
IL (3) IL145450A0 (enExample)
IS (1) IS2743B (enExample)
MA (1) MA26729A1 (enExample)
MX (1) MXPA01011018A (enExample)
MY (1) MY133378A (enExample)
NO (1) NO327612B1 (enExample)
NZ (1) NZ514465A (enExample)
OA (1) OA11877A (enExample)
PA (1) PA8493801A1 (enExample)
PE (1) PE20010112A1 (enExample)
PL (1) PL207610B1 (enExample)
RS (1) RS52134B (enExample)
SK (1) SK287535B6 (enExample)
SV (1) SV2004000061A (enExample)
TN (1) TNSN00093A1 (enExample)
TR (1) TR200103104T2 (enExample)
TW (2) TWI272264B (enExample)
UA (1) UA74145C2 (enExample)
UY (1) UY26129A1 (enExample)
WO (1) WO2000066522A1 (enExample)
ZA (1) ZA200108846B (enExample)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL207610B1 (pl) * 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
CA2417826A1 (en) 2000-08-05 2002-02-14 Glaxo Group Limited 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
IL146057A (en) * 2000-10-27 2007-09-20 Pfizer Prod Inc A process for the preparation of modulators of a non-steroidal glucocorticoid receptor
EP1201649B1 (en) * 2000-10-28 2006-05-31 Pfizer Products Inc. Glucocorticoid receptor modulators
ES2246292T3 (es) 2000-10-30 2006-02-16 Pfizer Products Inc. Moduladores de receptor glucocorticoide.
AR033290A1 (es) 2001-04-30 2003-12-10 Glaxo Group Ltd Derivados antiinflamatorios de androstano
US8193172B2 (en) 2001-11-23 2012-06-05 Pop Test Cortisol Llc Methods for the treatment of major depressive disorder using glucocorticoid receptor antagonists
WO2003059267A2 (en) * 2001-12-21 2003-07-24 Rhode Island Hospital SELECTIVE 11β-HSD INHIBITORS AND METHODS FOR USE THEREOF
US20060148725A1 (en) * 2001-12-21 2006-07-06 The Miriam Hospital Selective 11beta HSD inhibitors and methods of use thereof
EP1467982B8 (en) 2002-01-14 2007-04-11 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
JP4324480B2 (ja) * 2002-03-26 2009-09-02 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド グルココルチコイドミメティクス、その製法、医薬組成物、及び使用
EP1490317A1 (en) 2002-03-26 2004-12-29 Boehringer Ingelheim Pharmaceuticals Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7186864B2 (en) 2002-05-29 2007-03-06 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7074806B2 (en) * 2002-06-06 2006-07-11 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
WO2004005229A1 (en) * 2002-07-08 2004-01-15 Pfizer Products Inc. Modulators of the glucocorticoid receptor
CA2496175A1 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted hihydroquinolines as glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
NZ538932A (en) * 2002-08-29 2007-04-27 Boehringer Ingelheim Pharma 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative disease
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
BR0314872A (pt) * 2002-10-18 2005-08-02 Pfizer Prod Inc Ligandos do receptor canabinóide e usos dos mesmos
US20060052354A1 (en) * 2002-11-05 2006-03-09 Corcept Therapeutics, Inc. Methods for treating migraine
CA2504751C (en) * 2002-11-05 2013-02-05 Corcept Therapeutics, Inc. Methods for treating gastroesophageal reflux disease
EP1583745A1 (en) 2003-01-03 2005-10-12 Boehringer Ingelheim Pharmaceuticals Inc. 1-propanol and 1-propylamine derivatives and their use as glucocorticoid ligands
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
US20050020550A1 (en) * 2003-04-29 2005-01-27 Morris David J. Selective testicular 11beta-HSD inhibitors and methods of use thereof
US8097606B2 (en) 2003-07-23 2012-01-17 Corcept Therapeutics, Inc. Antiglucocorticoids for the treatment of catatonia
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
UY28526A1 (es) 2003-09-24 2005-04-29 Boehringer Ingelheim Pharma Miméticos de glucocorticoides, métodos de preparación composiciones farmacéuticas y usos de los mismos
TW200517114A (en) 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
JP4468369B2 (ja) 2003-10-16 2010-05-26 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド ある種のトリフルオロメチル置換アルコールの立体選択的合成
EP1685110A1 (en) * 2003-11-13 2006-08-02 Pfizer Products Inc. Octahydrophenanthrene hydrazide derivatives useful as glucocorticoid receptor modulators
JP2007512337A (ja) 2003-11-21 2007-05-17 コンビナトアールエックス インコーポレーティッド 炎症性障害の治療のための方法および試薬
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795272B2 (en) * 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US20050261292A1 (en) * 2004-05-19 2005-11-24 Solvay Pharmaceuticals Gmbh Pharmaceutical composition containing N-sulfamoyl-N'-arylpiperazines for the treatment or inhibition of obesity and related conditions
US20090156565A1 (en) * 2004-12-03 2009-06-18 The Children's Hospital Of Philadelphia Composition and use thereof in enhancing a therapeutic effect of an antiepileptic drug
PE20060776A1 (es) 2004-12-27 2006-09-26 Boehringer Ingelheim Pharma Mimeticos de glucocorticoides, metodos para prepararlos y composiciones farmaceuticas
US8067433B2 (en) 2005-11-09 2011-11-29 Zalicus Inc. Methods, compositions, and kits for the treatment of ophthalmic disorders
US7640389B2 (en) * 2006-02-28 2009-12-29 Freescale Semiconductor, Inc. Non-volatile memory having a multiple block erase mode and method therefor
US20080045475A1 (en) * 2006-08-20 2008-02-21 Phillip Edward Littmann Elemental cellular therapy is a genetic, cellular and disease-modifying therapy which enhances the systemic conduct of genetic and cellular transmethylation activity resulting in enhancement of concerted genetic and cellular metabolic, physiologic and homeostatic processes
MX2009005264A (es) * 2006-12-06 2009-05-28 Boehringer Ingelheim Int Mimeticos de glucocorticoides, metodos para su fabricacion, composiciones farmaceuticas y usos de los mismos.
DK2114970T3 (da) 2007-02-02 2011-09-19 Pfizer Prod Inc Tricykliske forbindelser og deres anvendelse som glucocorticoidreceptormodulatorer
UZ4378C (en) * 2007-02-02 2011-07-29 Pfizer Prod Inc Tricyclic compounds and their use as glucocorticoid receptor modulators
DK2300472T3 (da) * 2008-06-06 2012-04-10 Boehringer Ingelheim Int Glucocorticoidmimetika, fremgangsmåder til disses fremstilling, farmaceutiske sammensætninger samt anvendelser deraf
BRPI0917212A2 (pt) 2008-07-28 2015-11-10 Pfizer compostos de fenantrenona, seus usos na preparação de composições, e composições compreendendo os referidos compostos
US20100092479A1 (en) * 2008-08-18 2010-04-15 Combinatorx (Singapore) Pte. Ltd. Compositions and methods for treatment of viral diseases
CN101338200B (zh) * 2008-08-20 2011-08-17 石家庄国大工业有限公司 一种tn型液晶材料的混合物
ES2745628T3 (es) 2008-11-07 2020-03-03 Univ Sheffield Medicamento y método de diagnóstico
US20120220590A1 (en) 2009-07-31 2012-08-30 Thombare Pravin S Novel compounds as modulators of glucocorticoid receptors
CN102480964B (zh) 2009-08-31 2015-07-08 默沙东公司 吡喃基芳基甲基苯并喹唑啉酮m1受体正向别构调节剂
CN103180288B (zh) * 2010-10-27 2015-03-25 希格马托制药工业公司 具有生物学特性的二萜类衍生物
BR112013033777A2 (pt) * 2011-03-15 2016-09-13 Abbvie Inc moduladores de receptor de hormônio nuclear
WO2013041599A1 (en) * 2011-09-21 2013-03-28 Givaudan Sa Pyridine derivates and their use as umami tastants
TW201422590A (zh) 2012-09-07 2014-06-16 Abbvie Inc 雜環核激素受體調節劑
EP2935284A4 (en) 2012-12-21 2016-04-27 Abbvie Inc HETEROCYCLIC MODULATORS OF HORMONE NUCLEAR RECEPTORS
BR112015021990A2 (pt) * 2013-03-14 2017-07-18 Bristol Myers Squibb Co moduladores de gpr120 de ácido biciclo [2.2.1]
CZ305733B6 (cs) * 2014-08-26 2016-02-24 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Amfifilní sloučeniny s neuroprotektivními účinky
SK592017A3 (sk) * 2017-07-04 2019-01-08 Saneca Pharmaceuticals A. S. Spôsob prípravy morfínanových zlúčenín
EP3821220B1 (en) 2018-08-22 2024-11-13 University of Utah Research Foundation Force and torque sensor for prosthetic and orthopedic devices
US12070398B2 (en) 2018-08-28 2024-08-27 University Of Utah Research Foundation Variable transmission for assistive prosthesis device
JP7516394B2 (ja) 2019-01-22 2024-07-16 アクリベス ビオメディカル ゲーエムベーハー 皮膚創傷治癒不全を治療するための選択的グルココルチコイド受容体モジュレーター
AU2020239920A1 (en) * 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US12048668B2 (en) 2020-03-20 2024-07-30 The University Of Utah Research Foundation Self-aligning mechanisms in passive and powered exoskeletons
WO2022232025A1 (en) * 2021-04-26 2022-11-03 Alkermes, Inc. Substituted amide macrocyclic compounds with orexin-2 receptor agonist activity

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4514056Y1 (enExample) 1965-09-09 1970-06-15
US3516993A (en) * 1967-03-15 1970-06-23 Sandoz Ag Benzylidene-substituted nitrogenous heterocyclic compounds
US3683091A (en) 1967-11-13 1972-08-08 Wataru Nagata Certain phenanthrene compounds for treatment of acne
JPS50111098A (enExample) * 1974-02-18 1975-09-01
JPS6183138A (ja) 1984-09-28 1986-04-26 Harima Kasei Kogyo Kk ３−デオキシアフィディコリンの製造方法
FR2576025B1 (fr) * 1985-01-14 1987-01-23 Roussel Uclaf Nouveaux steroides substitues en position 10, leur procede et les intermediaires de preparation, leur application comme medicaments, les compositions pharmaceutiques les contenant
JPS61271216A (ja) 1985-05-27 1986-12-01 Mitsubishi Chem Ind Ltd 抗腫瘍剤
JPS6256422A (ja) 1985-09-04 1987-03-12 Mitsubishi Chem Ind Ltd 抗菌剤
JPH07100357B2 (ja) 1986-03-11 1995-11-01 三菱化学株式会社 繊維補強セメントモルタル成形体
US5039706A (en) 1987-11-30 1991-08-13 Du Pont Merck Pharmaceutical Company Antiinflammatory PLA2 inhibitors
US5116865A (en) * 1990-09-05 1992-05-26 Peters Richard H 15,16-seco-19-nor progestins
JPH06263688A (ja) 1991-09-04 1994-09-20 Otsuka Pharmaceut Factory Inc フェナンスレン誘導体
EP0676196A1 (en) 1993-10-13 1995-10-11 Otsuka Pharmaceutical Co., Ltd. Nitrogen monoxide synthesis inhibitor
DK0683172T3 (da) 1994-05-19 1998-03-30 Akzo Nobel Nv 11,21-bisphenyl-19-norpregnanderivater
JPH0952899A (ja) 1994-09-30 1997-02-25 Tsumura & Co ロイコトリエン拮抗剤
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US5767113A (en) 1995-05-10 1998-06-16 The Salk Institute For Biological Studies Compounds useful for concurrently activating glucocorticoid-induced response and reducing multidrug resistance
US5725694A (en) * 1996-11-25 1998-03-10 Reynolds Metals Company Free-machining aluminum alloy and method of use
FR2757400B1 (fr) 1996-12-19 1999-12-17 Hoechst Marion Roussel Inc Application des composes antiglucocorticoides dans le traitement des psychoses ou des comportements addictifs
WO1998027986A1 (en) 1996-12-24 1998-07-02 Zymogenetics, Inc. Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
IL122740A (en) * 1997-01-15 2003-09-17 Akzo Nobel Nv 16-hydroxy-11-(substituted phenyl)-estra-9,4-diene derivatives, their preparation and pharmaceutical compositions containing them
EP0903146A1 (en) 1997-09-23 1999-03-24 Applied Research Systems ARS Holdings N.V. 21-Hydroy-6,19-oxidoprogesterone (210h-60p) as antiglucocorticoid
PL207610B1 (pl) * 1999-04-30 2011-01-31 Pfizer Prod Inc Związki modulujące receptory glukokortykoidowe, ich zastosowanie do wytwarzania leku i środek farmaceutyczny

Similar Documents

Publication Publication Date Title
JP5588040B2 (ja) Ｓ１ｐ１／ｅｄｇ１受容体アゴニストとしてのアミノ−ピリジン誘導体
US12145924B2 (en) Lysophosphatidic acid receptor 1 (LPAR1) inhibitor compounds
US8106078B2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
JP2008511683A5 (enExample)
US8772502B2 (en) Alkylsulfinyl-substituted thiazolide compounds
JP2010513435A5 (enExample)
JP2010504913A5 (enExample)
JP2002529532A5 (enExample)
JP2009519965A5 (enExample)
JP2007535551A5 (enExample)
US20110015240A1 (en) Thiazole derivative and use thereof as vap-1 inhibitor
JP2013532726A5 (enExample)
HRP20110335T1 (hr) Supstituirani biciklolaktamski spojevi
JP2007531744A5 (enExample)
JP2009531280A5 (enExample)
JP2006517939A5 (enExample)
CN103102348B (zh) 噁二唑类化合物及其制备方法、药物组合物及其用途
ES2369634T3 (es) Derivados de benzamidina novedosos, procedimiento para la preparación de los mismos y composición farmacéutica que comprende los mismos.
JP2013527847A5 (enExample)
NZ592297A (en) 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
JP2005500286A5 (enExample)
JP2012524110A5 (enExample)
JP2007502817A5 (enExample)
JP2011517674A (ja) 嚢胞性線維症膜コンダクタンス制御因子の水溶性小分子阻害剤
JP6378179B2 (ja) 新規化合物，有機カチオントランスポーター３の検出剤及び活性阻害剤